Searched for
GLENMARK PHARMACEUTICAL
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...23 May, 2026, 10.24 PM IST- Capitalmind Flexi Cap Fund exits RIL and 2 others, hikes stake in Titan Company, MCX and 16 other stocks in AprilCapitalmind Flexi Cap Fund exited Reliance Industries, Bank of Baroda, and L&T Finance in April. The fund also increased stakes in Titan Co...15 May, 2026, 11.43 AM IST
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...10 May, 2026, 08.50 AM IST
- Nifty finds support: Nagaraj Shetti spots 2 breakout stocks worth watchingNifty's Monday pullback is a technical dip, not a trend reversal, says HDFC Securities analyst Nagaraj Shetti. After forming a higher botto...14 Apr, 2026, 01.07 PM IST
- I-Sec maintains Reduce call on Glenmark Pharma, raises target price to Rs 1,300ICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals, revising the target price to Rs 1,300. The brokerage anticipates reve...29 May, 2025, 09.31 AM IST
- Reduce Glenmark Pharmaceuticals, target price Rs 1,265: ICICI SecuritiesICICI Securities maintains a Reduce call on Glenmark Pharmaceuticals with a target price of Rs 1,265. The current market price is Rs 1365.9...20 Feb, 2025, 09.51 AM IST
- Glenmark Pharmaceuticals Q3 Results: PAT at Rs 348 crore versus YoY loss, revenue up 35%Glenmark Pharmaceuticals Q3 Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY...14 Feb, 2025, 08.08 PM IST
- Buy Glenmark Pharmaceuticals, target price Rs 1,779: Choice Equity BrokingChoice Equity Broking has issued a buy call for Glenmark Pharmaceuticals, setting a target price of Rs 1,779. The brokerage projects robust...21 Nov, 2024, 09.11 AM IST
- Reduce Glenmark Pharmaceuticals, target price Rs 780: ICICI SecuritiesGlenmark Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the y...20 Feb, 2024, 10.29 AM IST
- Reduce Glenmark Pharmaceuticals, target price Rs 660: ICICI SecuritiesGlenmark Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the y...16 Nov, 2023, 10.46 AM IST
- Glenmark Pharmaceuticals launches generic version of diuretic Bumetanide injectionThe launch affirms commitment to Glenmark's continued focus on institutional business, company Senior Vice President, Business Development ...10 Jan, 2023, 11.11 AM IST
- Buy Glenmark Pharmaceuticals Ltd with a target of Rs 760: Ashwani Gujral'Glenmark Pharmaceuticals Ltd is a 'BUY' call with a target of Rs 760 and a stop loss of Rs 725.'04 Feb, 2015, 03.12 PM IST
- Buy Glenmark Pharmaceuticals Ltd with a target of Rs 749: Sandeep Wagle'Glenmark Pharmaceuticals Ltd is a 'BUY' call with a target of Rs 749 and a stop loss of Rs 732.'19 Jan, 2015, 11.15 AM IST
- Buy Glenmark Pharmaceuticals Ltd with a target of Rs 851: Sandeep Wagle"Glenmark Pharmaceuticals Ltd is a ‘BUY’ call with a target of Rs 851 and a stop loss of Rs 810."12 Dec, 2014, 11.42 AM IST
- Buy Glenmark Pharmaceuticals Ltd with a target of Rs 855: Mitesh Thacker"Glenmark Pharmaceuticals Ltd is a ‘BUY’ call with a target of Rs 855 and a stop loss of Rs 805."12 Dec, 2014, 11.17 AM IST
- Glenmark Pharmaceuticals gains 7% on Q2 results; brokerages maintain buyThe company had posted a net profit of Rs 56.58 crore for the quarter ended September 30, 2011, Glenmark Pharmaceuticals said in a statemen...31 Oct, 2012, 11.27 AM IST
- Glenmark Pharmaceuticals Q2 net up nearly three fold at Rs 156.75 crGlenmark Pharmaceuticals today said its consolidated net profit rose by nearly three fold to Rs 156.75 crore for the quarter ended Septembe...30 Oct, 2012, 08.54 PM IST
Load More
